Maxim Group analyst Caroline Palomeque maintained a Buy rating on Neurotrope (NTRP) today and set a price target of $16. The company’s shares opened today at $4.03, close to its 52-week low of $3.33.
Palomeque commented:
“Neurotrope reported 4Q18 and FY2018 with net losses of $3.8M and $11.1M, respectively. The company ended the period with $28.8M in cash on the balance sheet, including $20.5M in net proceeds from an equity financing in December 2018.”
According to TipRanks.com, Palomeque has 0 stars on 0-5 star ranking scale with an average return of -14.1% and a 31.3% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, Anavex Life Sciences, and AzurRx BioPharma Inc.
Currently, the analyst consensus on Neurotrope is a Moderate Buy with an average price target of $16.
See today’s analyst top recommended stocks >>
Based on Neurotrope’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.17 million. In comparison, last year the company had a GAAP net loss of $4.31 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. It operates through the following geographical segments: US; European Union; Japan; and China and India.
